These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 11082141

  • 1. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [Abstract] [Full Text] [Related]

  • 2. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 3. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B, LIFE Study Group.
    Hypertension; 2000 Jan 12; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [Abstract] [Full Text] [Related]

  • 4. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN, Devereux RB, Okin PM.
    J Electrocardiol; 2014 Jan 12; 47(5):630-5. PubMed ID: 25052475
    [Abstract] [Full Text] [Related]

  • 5. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009 Nov 17; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 7. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    J Hum Hypertens; 2011 Mar 17; 25(3):178-85. PubMed ID: 20505749
    [Abstract] [Full Text] [Related]

  • 8. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.
    JAMA; 2006 Sep 13; 296(10):1242-8. PubMed ID: 16968848
    [Abstract] [Full Text] [Related]

  • 9. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM, Hille DA, Kjeldsen SE, Devereux RB.
    J Am Heart Assoc; 2017 Nov 18; 6(11):. PubMed ID: 29151037
    [Abstract] [Full Text] [Related]

  • 10. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
    Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Hypertension; 1998 Dec 18; 32(6):989-97. PubMed ID: 9856962
    [Abstract] [Full Text] [Related]

  • 11. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlöf B, Devereux RB.
    Am J Hypertens; 2010 Jul 18; 23(7):786-93. PubMed ID: 20395941
    [Abstract] [Full Text] [Related]

  • 12. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlöf B.
    Am J Hypertens; 2001 Aug 18; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [Abstract] [Full Text] [Related]

  • 13. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

  • 14. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Jan 03; 113(1):67-73. PubMed ID: 16365195
    [Abstract] [Full Text] [Related]

  • 15. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
    Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahlöf B, Devereux RB.
    Am J Hypertens; 2002 Aug 03; 15(8):663-71. PubMed ID: 12160187
    [Abstract] [Full Text] [Related]

  • 16. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahlöf B.
    J Hum Hypertens; 2004 Jun 03; 18(6):403-9. PubMed ID: 15057252
    [Abstract] [Full Text] [Related]

  • 17. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators.
    Am Heart J; 2003 May 03; 145(5):919-25. PubMed ID: 12766755
    [Abstract] [Full Text] [Related]

  • 18. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B.
    J Hypertens; 2002 Jul 03; 20(7):1445-50. PubMed ID: 12131543
    [Abstract] [Full Text] [Related]

  • 19. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.
    J Hypertens; 2014 Dec 03; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [Abstract] [Full Text] [Related]

  • 20. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
    Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, Devereux RB, Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators.
    Hypertension; 2008 Jul 03; 52(1):100-6. PubMed ID: 18504323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.